{"nctId":"NCT02613871","briefTitle":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection","startDateStruct":{"date":"2015-12-22","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":111,"armGroups":[{"label":"LDV/SOF","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Individuals ≥ 40 kg in weight with chronic genotype 1 or 2 HCV and HBV coinfection\n* Individuals must not be taking or requiring treatment with HBV antiviral therapy at screening. For participants that are HBV treatment experienced, the most recent treatment must have been completed at least 6 months prior to Day 1.\n* Cirrhosis determination by Fibroscan\n* Screening laboratory values within defined thresholds\n* Use of two effective contraception methods if female or male is of childbearing potential\n\nKey Exclusion Criteria:\n\n* Current or prior history of clinically-significant illness or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol\n* Pregnant or nursing female\n* Infection with human immunodeficiency virus (HIV) or hepatitis delta virus (HDV)\n* Hepatocellular carcinoma (HCC) or other malignancy\n* Current or prior history of clinical hepatic decompensation\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantification (LLOQ; 15 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Any Adverse Event Leading to Permanent Discontinuation of Study Drug","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)","description":"SVR4 was defined as HCV RNA \\< LLOQ (15 IU/mL) at 4 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ While on Treatment","description":"LLOQ = 15 IU/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Posttreatment Weeks 24, 36, 48, 60, 72, 84, 96, and 108","description":"LLOQ = 15 IU/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"HCV RNA Change From Baseline While on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.14","spread":"0.551"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.63","spread":"0.702"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.73","spread":"0.727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.73","spread":"0.727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.73","spread":"0.727"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as :\n\n* Breakthrough (confirmed HCV RNA ≥ LLOQ \\[15 IU/mL\\] after having previously had HCV RNA \\< LLOQ while on treatment), or\n* Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n* Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment), or\n* Relapse (HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma HBV DNA Change From Baseline While on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.366"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.705"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"0.906"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.746"}]}]}]},{"type":"SECONDARY","title":"Plasma HBV DNA Change From Baseline at Posttreatment Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, and 108","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"0.955"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"1.036"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"1.190"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"1.269"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"1.399"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"1.131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"1.008"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"0.963"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.923"}]}]}]},{"type":"SECONDARY","title":"HBsAg Level Change From Baseline While on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.184"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.181"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.185"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"0.234"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.266"}]}]}]},{"type":"SECONDARY","title":"HBsAg Level Change From Baseline at Posttreatment Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, and 108","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.347"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.338"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.405"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.484"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.526"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.664"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.619"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.608"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"0.618"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.658"}]}]}]},{"type":"SECONDARY","title":"Serum LOXL-2 Level Change From Baseline While on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"29.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":"26.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15","spread":"27.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22","spread":"36.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27","spread":"36.0"}]}]}]},{"type":"SECONDARY","title":"Serum LOXL-2 Level Change From Baseline at Posttreatment Weeks 4, 12, and 36","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30","spread":"45.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32","spread":"51.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41","spread":"53.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Required HBV Therapy During the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Fibrosis Status as Assessed by Fibroscan Score at Posttreatment Weeks 12, 60, and 108","description":"FibroScan is a non-invasive device that assesses the hardness (or stiffness) of the liver using the technique of transient elastography. FibroScan results range from 2.5 kPa to 75 kPa with higher scores indicating greater liver stiffness. Per protocol, cirrhosis status was determined as follows:\n\n* Presence of cirrhosis = FibroScan result of \\> 12.5 kPa\n* Absence of cirrhosis = FibroScan result of ≤ 12.5 kPa","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"7.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"4.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"4.79"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Develop Hepatocellular Carcinoma (HCC) During the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":111},"commonTop":["Headache","Upper respiratory tract infection","Fatigue"]}}}